Tag: Cancer

[OncoHost in PR Newswire] OncoHost to present proteomics-based biomarker model for clinical benefit to immunotherapy in NSCLC patients at SITC 2022

BINYAMINA, Israel , Nov. 7, 2022 /PRNewswire/ — OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has developed a novel predictive model for clinical benefit of immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients. The model is based on proteomic profiling of pre-treatment blood samples, combined with machine learning analysis that accurately predicts clinical benefit probability at twelve months, outperforming the predictive capabilities of the existing PD-L1 biomarker. The study was conducted using OncoHost’s first-of-its-kind PROphet® platform, and will be presented as a poster at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting. Read...

Read More

[OncoHost in PR Newswire] OncoHost announces new executive appointments ahead of imminent launch of its precision oncology platform

BINYAMINA, Israel, Oct. 3, 2022 /PRNewswire/ — OncoHost, a global leader in precision oncology for improved personalized cancer therapy, today announced two appointments to its executive team. Seasoned healthcare executive James “Jim” Whelan joins OncoHost’s board of directors and commercial oncology expert Chris Dingman joins as chief commercial officer. Read...

Read More

[OncoHost in PR Newswire] JITC publishes OncoHost study identifying predictive proteomic signature to analyze treatment resistance in NSCLC patients

BINYAMINA, Israel, June 21, 2022 /PRNewswire/ — OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced a peer-reviewed article published in Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal. The study highlights the role of blood plasma proteomic profiling for assessing resistance in non-small cell lung cancer (NSCLC) patients being treated with immune checkpoint inhibitors (ICIs). Read...

Read More

Latest from Twitter